{
    "organizations": [],
    "uuid": "864e04bc33df8488fa3907de2f278a1745de4edf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-ablynx-fy-operating-loss-widens-to/brief-ablynx-fy-operating-loss-widens-to-54-2-million-euros-idUSFWN1QC05S",
    "ord_in_thread": 0,
    "title": "BRIEF-Ablynx FY Operating Loss Widens To 54.2‍​ Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - ABLYNX NV:\n* FY OPERATING LOSS OF EUR 54.2‍​ MILLION VERSUS LOSS OF EUR 28.6 MILLION YEAR AGO\n* FY NET LOSS OF EUR 108.5‍​ MILLION VERSUS LOSS OF EUR 1.1 MILLION YEAR AGO\n* CASH POSITION AT DEC 31 EUR 354.3‍​ MILLION VERSUS EUR 235.4 MILLION YEAR AGO\n* FY TOTAL REVENUE AND GRANT INCOME EUR ‍​55.5 MILLION VERSUS EUR 85.2 MILLION YEAR AGO\n* MAY RECEIVE MARKETING AUTHORISATION FOR CAPLACIZUMAB IN ATTP IN Q3 2018\n* FOR ALX-0171, A PHASE II STUDY TO BE INITIATED IN H1 2018\n* RESULTS FROM ONGOING ALX-0171 PHASE IIB STUDY IN RSV-INFECTED HOSPITALISED INFANTS ARE EXPECTED IN Q4 2018\n* PHASE II RESULTS FOR VOBARILIZUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS EXPECTED IN H1 2018\n* EXPECTS UP TO THREE NANOBODIES TO ENTER PHASE I STUDIES FROM OUR COLLABORATIVE PROGRAMMES DURING 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-22T14:21:00.000+02:00",
    "crawled": "2018-02-23T15:39:51.021+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "ablynx",
        "nv",
        "fy",
        "operating",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "fy",
        "net",
        "loss",
        "eur",
        "million",
        "versus",
        "loss",
        "eur",
        "million",
        "year",
        "ago",
        "cash",
        "position",
        "dec",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "ago",
        "fy",
        "total",
        "revenue",
        "grant",
        "income",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "ago",
        "may",
        "receive",
        "marketing",
        "authorisation",
        "caplacizumab",
        "attp",
        "q3",
        "phase",
        "ii",
        "study",
        "initiated",
        "h1",
        "result",
        "ongoing",
        "phase",
        "iib",
        "study",
        "hospitalised",
        "infant",
        "expected",
        "q4",
        "phase",
        "ii",
        "result",
        "vobarilizumab",
        "systemic",
        "lupus",
        "erythematosus",
        "patient",
        "expected",
        "h1",
        "expects",
        "three",
        "nanobodies",
        "enter",
        "phase",
        "study",
        "collaborative",
        "programme",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}